Department of Obstetrics and Gynaecology

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer (2020) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Journal article Phase III PAOLA-1/ENGOT-OV25 Trial: Olaparib Plus Bevacizumab (BEV) As Maintenance Therapy in Patients (PTS) with Newly Diagnosed, Advanced Ovarian Cancer (OC) Treated with Platinum-Based Chemotherapy (PCH) Plus Bev (2020) De Gregorio N, Harter P, Sehouli L, Canzler U, Marme F, Buderath P, Lueck HJ, et al. Conference contribution Germline (G)BRCA1/2 Mutations (M) and Hematological Toxicities in Patients (PTS) with Triple Negative Breast Cancer (TNBC) Treated with Neoadjuvant Chemotherapy (NACT) (2020) Furlanetto J, Moebus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Luebbe K, et al. Conference contribution A Randomized, Double-Blind, Phase III Trial of Neoadjuvant Chemotherapy (NACT) with atezolizumab/Placebo in Patients with Triple-Negative Breast Cancer (TNBC) Followed by Adjuvant Continuation of atezolizumab/Placebo (Gepardouze) (2020) Loibl S, Jackisch C, Seiler S, Rastogi P, Huober L, Denkert C, Schneeweiss A, et al. Conference contribution Germline Mutation Status and Therapy Response in High-Risk Early-Stage Breast Cancer: a Secondary Analysis of the Geparocto Randomized Clinical Trial (NCT02125344) (2020) Pohl-Rescigno E, Hauke J, Rhiem K, Moebus V, Furlanetto J, Denkert C, Fasching P, et al. Conference contribution First Results of the Detect IVA Study -Everolimus Treatment in Patients with HER2-Negative, Hormone-Receptor Positive Metastatic Breast (MBC) Cancer and Circulating Tumor Cells (CTC) (2020) Friedl TWP, Krause S, Fasching P, Schneeweiss A, Mueller V, Riethdorf S, Taran FA, et al. Conference contribution Is there an Advantage of Lymphadenectomy for Overall and Recurrence-Free Survival in Endometrial Carcinoma Type I FIGO IB G1-2? A Retrospective Population-Based Cohort Analysis (2020) Hassas D, Papathemelis T, Gerken M, Scharl S, Scharl A, Lux MP, Beckmann M, et al. Conference contribution Impact - Implementing Patients' Competence in Oral Breast Cancer Therapy - A Randomized, Controlled Study of Standardized Patient Coaching Versus Patient Management According to Local Practice for Patients with HR Positive HER2 Negative Metastatic Breast Cancer Treated with Abemaciclib (2020) Welslau M, Nabieva N, Decker T, Belleville E, Knapp O, Häberle L, Fasching P, Tesch H Conference contribution Accelerated partial breast irradiation: Macrophage polarisation shift classification identifies high-risk tumours in early hormone receptor-positive breast cancer (2020) Schnellhardt S, Erber R, Büttner-Herold M, Rosahl MC, Ott O, Strnad V, Beckmann M, et al. Journal article A network analysis to identify mediators of germline-driven differences in breast cancer prognosis (2020) Escala-Garcia M, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Ashworth A, Auer PL, et al. Journal article